II. IN THE CLAIMS (CLEAN SHEET)

2. A peptide having 16 to 55 amino acid residues, comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTFIKSVPPFL (SEQ ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17), PPFLRTHGFDGLDLAW (SEQ ID NO: 18), HGFDGLDLAWLYPGRR (SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20), TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLDFISIMT (SEQ ID NO: 29), QHLDFISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPDRFS (SEQ IS NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), PASKLVMGIPTFGRSF (SEQ ID NO: 39, GTLAYYEICDFLRGAT (SEQ ID NO: 46), EICDFLRGATVHRTLG (SEQ ID NO: 47), RGATVHRTLGQQVPYA (SEQ ID NO: 48), VKSKVQYLKDRQLAGA (SEQ ID NO: 53), YLKDRQLAGAMVWALD (SEQ ID NO: 54), LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD (SEQ ID NO: 56) and DFQGSFCGQDLRFPLT (SEQ ID NO: 57).

3. The peptide according to claim 2, comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), QHLDFISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPDRFS (SEQ ID NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), YLKDRQLAGAMVWALD (SEQ ID NO: 54) and LAGAMVWALDLDDFQG (SEQ ID NO: 55).

4. The peptide according to therefore claim 3, comprising at least one of the amino acid sequences YTSWSQYREGDGSCFP (SEQ ID NO: 2), SPLFRGQEDASPDRFS (SEQ ID NO: 34), MLRLGAPASKLVMGIP (SEQ ID NO: 38), YLKDRQLAGAMVWALD (SEQ ID NO: 54) and LAGAMVWALDLDDFQG (SEQ ID NO: 55).

5. The peptide according to claim 3, which is a hexadecapeptide.

7. A pharmaceutical composition comprising one or more peptides according to claim 2, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising one or more peptides according to claim 5, and a pharmaceutically acceptable carrier.

11. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides according to claim 2.

12. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides according to claim 5.

13. A pharmaceutical composition comprising one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), PNLKTLLSVGGWNFGS (SEQ ID NO:12), NTQSRRTFIKSVPPFL (SEQ ID NO:16), TFIKSVPPFLRTHGFD (SEQ ID NO:17), PPFLRTHGFDGLDLAW (SEQ ID NO:18), HGFDGLDLAWLYPGRR (SEQ ID NO:19),

DLAWLYPGRRDKQHFT (SEQ ID NO:20), TIDSSYDIAKISQHLD (SEQ ID NO:28), DIAKISQHLDFISIMT (SEQ ID NO:29), QHLDFISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), PASKLVMGIPTFGRSF (SEQ ID NO:39), GTLAYYEICDFLRGAT (SEQ ID NO:46), EICDFLRGATVHRTLG (SEQ ID NO:47), RGATVHRTLGQQVPYA (SEQ ID NO:48), VKSKVQYLKDRQLAGA (SEQ ID NO:53), YLKDRQLAGAMVWALD (SEQ ID NO:54), LAGAMVWALDLDDFQG (SEQ ID NO:55), WALDLDDFQGSFCGQD (SEQ ID NO:56) or DFQGSFCGQDLRFPLT (SEQ ID NO:57).

14. A pharmaceutical composition comprising one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), QHLDFISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), YLKDRQLAGAMVWALD (SEQ ID NO:54) and LAGAMVWALDLDDFQG (SEQ ID NO:55).

15. A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences LVCYYTSYS (SEQ ID NO:60), FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), FIKSVPPFL (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID

NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YKLDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO:77) or LDLDDFQGS (SEQ ID NO:78), and a pharmaceutically acceptable carrier.

16. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 13.

17. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 14.

III. In the Claims (Marked Sheet)

Please amend the claims as follows:

15. (Amended) A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences LVCYYTSYS (SEQ ID NO:60), FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), FIKSVPPFL (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YKLDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO:77) or LDLDDFQGS (SEQ ID NO:78), and a pharmaceutically acceptable carrier.

Sub C4

B1

IV. Conclusion

Applicants respectfully elect Group I with traverse and have preliminarily amended Claim 15 to make the scope identical with the product claims in U.S. Pat. No. 6,184,204, thereby requesting examination of Groups I-XXVI. The application is believed in a condition for allowance and Applicants respectfully request such action.

Please call the below undersigned attorney for any assistance in securing allowance of this application. Please charge deposit account number 02-2334 for any required fees.

Date: 1/17/02

Sincerely,



William P. Ramey, III
Reg. No. 44,295
AKZO Nobel, Intervet, Inc.
405 State Street
Millsboro, DE 19966
(302) 933-4034 telephone
(302) 934-4242 facsimile